---
schema_version: "secwatch.filing_event.v1"
accession: "0001401914-22-000085"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:38:09.240652+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Daré Q3 cash $40.4M; Ovaprene IDE approved; DARE-HRT1 positive efficacy data

## Summary
- Cash $40.4M at Sep 30, 2022 vs $51.7M Dec 31, 2021; R&D expense $4.5M (down from $10.4M).
- FDA approved IDE for Ovaprene pivotal Phase 3 contraceptive study; investigator meeting Dec 2022.
- Positive topline efficacy data from DARE-HRT1 Phase 1/2 study; PK data expected later Q4 2022.
- Sildenafil Cream 3.6% Phase 2b RESPOND subject screening completed; topline data targeted Q2 2023.
- XACIATO first commercial sale expected 1H 2023 under Organon license agreement.

## SEC filing metadata
- accession: 0001401914-22-000085
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000140191422000085/0001401914-22-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000140191422000085/dare-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001401914-22-000085
- JSON: https://secwatch.observer/filing/0001401914-22-000085.json
- Plain text: https://secwatch.observer/filing/0001401914-22-000085.txt

## Key facts
- Earnings Releases
  Dare Bioscience, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Dare Bioscience, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000140191422000085/0001401914-22-000085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.